Literature DB >> 30081793

Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising?

Ritika Rana1, Ruchika Sharma2, Anoop Kumar1.   

Abstract

Today's microbial infections' resistance to approved drugs, the emergence of new infectious diseases and lack of vaccines, create a huge threat to human health. Thus, there is an urgent need to create novel antimicrobial agents, but the high cost and prolonged timeline of novel drug discovery and development is the major barrier to make new drugs. Therefore, there is a need for specific cost effective approaches in order to identify new drugs for the treatment of various microbial infections. Drug repurposition is an alternative technique to find existing clinically approved drugs for other indications. This approach may enhance the portfolio of Pharmaceutical companies by reducing the time and money required for the development of new chemical entity. In literature, various studies have reported some encouraging results regarding the antimicrobial use of existing statin drugs. Further, some clinical studies have also shown the protective effect of statin drugs in reduction of the morbidity and mortality due to many infectious diseases but complete understanding is still lacking. Thus, there is a need for better understanding of the use of statin drugs, especially in the context of antimicrobial effects. In this review, we try to summarize the use of statin drugs in various infectious diseases and their proposed antimicrobial mechanism of action. Further, current challenges and future perspectives of repurposition of statin drugs as antimicrobial agents have also been discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Drug-resistance; antimicrobial activity; drug repurposition; microbial infections; statin drugs; treatment.

Mesh:

Substances:

Year:  2019        PMID: 30081793     DOI: 10.2174/1871526518666180806123230

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  6 in total

1.  Human β-Defensin 118 Attenuates Escherichia coli K88-Induced Inflammation and Intestinal Injury in Mice.

Authors:  Qian Lin; Qingqing Fu; Xiang Li; Yuheng Luo; Junqiu Luo; Daiwen Chen; Xiangbing Mao; Bing Yu; Ping Zheng; Zhiqing Huang; Jie Yu; Hui Yan; Jun He
Journal:  Probiotics Antimicrob Proteins       Date:  2020-11-13       Impact factor: 4.609

Review 2.  Review on plant antimicrobials: a mechanistic viewpoint.

Authors:  Bahman Khameneh; Milad Iranshahy; Vahid Soheili; Bibi Sedigheh Fazly Bazzaz
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-16       Impact factor: 4.887

3.  Expression and Functional Characterization of a Novel Antimicrobial Peptide: Human Beta-Defensin 118.

Authors:  Qian Lin; Kunhong Xie; Daiwen Chen; Bing Yu; Xiangbing Mao; Jie Yu; Junqiu Luo; Ping Zheng; Yuheng Luo; Hui Yan; Jun He
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

Review 4.  Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections.

Authors:  Chiara Sfogliarini; Giovanna Pepe; Arianna Dolce; Sara Della Torre; Maria Candida Cesta; Marcello Allegretti; Massimo Locati; Elisabetta Vegeto
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

5.  Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption.

Authors:  Qian Lin; Guoqi Su; Aimin Wu; Daiwen Chen; Bing Yu; Zhiqing Huang; Yuheng Luo; Xiangbing Mao; Ping Zheng; Jie Yu; Junqiu Luo; Jun He
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-26       Impact factor: 4.887

6.  Caffeic Acid Prevents Vascular Oxidative Stress and Atherosclerosis against Atherosclerogenic Diet in Rats.

Authors:  Ying Wang; Gurpreet Kaur; Manish Kumar; Ajay Singh Kushwah; Atul Kabra; Ritu Kainth
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-13       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.